Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...